Dr. Christine Dailey Hirsemann, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 90 Libbey Parkway, Suite 105, S Weymouth, MA 02189 Phone: 339-201-4120 Fax: 781-545-8117 |
Kimberly A Dever, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 90 Libbey Parkway, Suite 105, S Weymouth, MA 02189 Phone: 339-201-4120 Fax: 781-545-8117 |
Dr. Karen Mary Toujouse, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 90 Libbey Parkway, Suite 105, S Weymouth, MA 02189 Phone: 339-201-4120 Fax: 781-545-8117 |
Dr. Julianne Arena, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 90 Libbey Parkway, Suite 105, S Weymouth, MA 02189 Phone: 339-201-4120 Fax: 781-545-8117 |
Dr. Darlyne A Johnson, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 90 Libbey Parkway, Suite 105, S Weymouth, MA 02189 Phone: 339-201-4120 Fax: 781-545-8117 |
Carolyn Martha Mcnulty, D.O. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 90 Libbey Parkway, Suite 105, S Weymouth, MA 02189 Phone: 339-201-4120 Fax: 781-545-8117 |
News Archive
American Scientific Resources, Inc., announces that the Disintegrator Plus(TM), the world's only FDA approved home needle destruction device (NDD), is in its first production run for ASR.
An investigational drug that binds bile acids in the stomach can reduce the severity of heartburn symptoms in patients with treatment-resistant gastroesophageal reflux disease (GERD) when combined with a proton pump inhibitor (PPI), a new study suggests.
People with severe depression are constantly despondent, lacking in drive, withdrawn and no longer feel joy. Most suffer from anxiety and the desire to take their own life. Approximately one out of every five people in Germany suffers from depression in the course of his/her life - sometimes resulting in suicide. People with depression are frequently treated with psychotherapy and medication.
Demographic trends worldwide show a progressively aging population and an increase in the overall medical complexity of elderly patients with cardiovascular disease.
FemmePharma Global Healthcare, a privately held women's health company dedicated to improving the quality of life for women, today announces completion of its Phase II clinical dose ranging/safety trial with FP 1097 in women suffering from urinary incontinence or overactive bladder.
› Verified 3 days ago